REVIEW

"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease

Chinthalapally V. Rao1 | Adam S. Asch2 | Daniel J. J. Carr3 | Hiroshi Y. Yamada1

1Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK, USA
2Stephenson Cancer Center, Department of Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK, USA
3Department of Ophthalmology, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK, USA

Correspondence
Hiroshi Y. Yamada and Chinthalapally V. Rao, Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center (OUHSC), 975 NE 10th St. BRC1207, Oklahoma City, OK 73104, USA.
Emails: Hiroshi-yamada@ouhsc.edu (H.Y.Y.); cv-rao@ouhsc.edu (C.V.R.)

Abstract
The cell cycle and its regulators are validated targets for cancer drugs. Reagents that target cells in a specific cell cycle phase (e.g., antimitotics or DNA synthesis inhibitors/replication stress inducers) have demonstrated success as broad-spectrum anticancer drugs. Cyclin-dependent kinases (CDKs) are drivers of cell cycle transitions. A CDK inhibitor, flavopiridol/alvocidib, is an FDA-approved drug for acute myeloid leukemia. Alzheimer's disease (AD) is another serious issue in contemporary medicine. The cause of AD remains elusive, although a critical role of latent amyloid-beta accumulation has emerged. Existing AD drug research and development targets include amyloid, amyloid metabolism/catabolism, tau, inflammation, cholesterol, the cholinergic system, and other neurotransmitters. However, none have been validated as therapeutically effective targets. Recent reports from AD-omics and preclinical animal models provided data supporting the long-standing notion that cell cycle progression and/or mitosis may be a valid target for AD prevention and/or therapy. This review will summarize the recent developments in AD research: (a) Mitotic re-entry, leading to the "amyloid-beta accumulation cycle," may be a prerequisite for amyloid-beta accumulation and AD pathology development; (b) AD-associated pathogens can cause cell cycle errors; (c) thirteen among 37 human AD genetic risk genes may be functionally involved in the cell cycle and/or mitosis; and (d) preclinical AD mouse models treated with CDK inhibitor showed improvements in cognitive/behavioral symptoms. If the "amyloid-beta accumulation cycle is an AD drug target" concept is proven, repurposing of cancer drugs may emerge as a new, fast-track approach for AD management in the clinic setting.

KEYWORDS
Alzheimer's disease (AD), amyloid-beta (Aβ), brain, cell cycle, chromosome instability (CIN), cohesinopathy, cyclin-dependent kinase (CDK) inhibitor, mitosis, mouse, Shugoshin 1 (Sgo1)
1 | ALZHEIMER’S DISEASE REPRESENTS A MAJOR ISSUE IN CONTEMPORARY MEDICINE

Alzheimer’s disease (AD) is a progressive, lethal, and incurable disease. While 3%–4% of AD is early-onset, in which patients show cognitive symptoms in their 40s–50s, over 96% of AD is late-onset, in which symptoms (most notoriously, memory loss and cognitive/behavior issues) first appear at age 65 or older. In late-onset cases, the patients live an average of four to eight years after diagnosis. As AD progresses, the patients gradually lose various social and physical functions, making disease management financially costly and emotionally burdensome for patients and caregivers. However, there has been no clinically effective medicine for AD therapy. Current FDA-approved AD medications, such as donepezil/Aricept (central acetylcholinesterase inhibitor) and memantine (N-methyl-D-aspartate [NMDA] receptor antagonist), are neuronal function modulators and can temporarily alleviate AD symptoms. These drugs do not address the pathological cause of AD and therefore do not cure AD. Unmet needs for AD drugs remain. Millions of individuals are affected by AD; for example, in the United States, 5.8 million people are living with AD in 2019 (https://www.alz.org/alzheimers-dementia/facts-figures; accessed 8/2/2019). The number of patients with AD is predicted to increase in upcoming decades, making AD an urgent issue in contemporary health care.

2 | COMPLEX AD PATHOLOGY LEADS TO TWO MAJOR LATE-STAGE AD BRAIN PATHOLOGIES: AMYLOID-BETA “PLAQUES” AND TAU/P-TAU NEUROFIBRILLARY “TANGLES”

Alzheimer’s disease development is accompanied by various pathological markers and events: cellular/intracellular amyloid-beta accumulation, amyloid-beta plaque and phospho-tau tangle pathology, synaptic degeneration, cognitive impairment, and abnormalities in other cellular biomarkers, such as functions of the oxidative stress pathway and mitochondria. Dissecting the order of these pathology and events is critical to identifying AD drug targets (Figure 1; “Complex Pathology of AD”). Among these major pathological changes in AD brains are (a) senile “plaques” composed of an accumulation of amyloid-beta and (b) neurofibrillary “tangles” that are mainly made of phosphorylated tau (Iqbal & Grundke-Iqbal, 2008). Accumulated amyloid-beta is neurotoxic and is widely considered to be the causal protein for AD development, that is, the amyloid-beta hypothesis (Hardy & Higgins, 1992; Hardy & Selkoe, 2002; Selkoe, 2001) and its successor, the amyloid-beta oligomer hypothesis (e.g., Cline, Bicca, Viola, & Klein, 2018). Soluble amyloid-beta 1-42 can form oligomers that cause synaptic failure, which leads to cognitive impairment and behavioral issues (Coleman, Federoff, & Kurlan, 2004; Klein, Stine, & Teplow, 2004). Thus, amyloid-beta accumulation with oligomer formation is considered the triggering event for AD development, leading to cascades of events, pathway activations, and other pathologies. The amount of amyloid-beta is a result of the balance between generation and catabolism; thus, pathways involved in amyloid-beta generation and catabolism have been of major research interest and are candidates for AD drug targeting (Hardy & Selkoe, 2002; Selkoe & Hardy, 2016).

Amyloid-beta is generated from the larger precursor protein amyloid precursor protein (APP) through proteolysis. Proteolytic enzymes involved in amyloid-beta generation (i.e., the amyloidogenic pathway) include beta-secretase (BACE) and gamma-secretase complex (Moussa-Pacha, Abdin, Omar, Alniss, & Al-Tel, 2019; Penke, Bogár, & Fülöp, 2017). Amyloid-beta can be removed through a proteolytic catabolism pathway. Sikanyika, Parkinson, Smith, and Kuruppu (2019) listed 10 proteases that can catabolize Aβ1-42. These proteases include nephrilysin, endothelin converting enzyme 1, and insulin-degrading enzyme. As the APOE4 variant increases the abundance of Aβ and risk of AD, an APOE-associated cholesterol pathway plays a role in Aβ dyshomeostasis (Selkoe, 2001; Yamazaki, Zhao, Caulfield, Liu, & Bu, 2019). Plaques are usually surrounded by glial cells, which play...
a role in immunological removal of plaques (Dong, Li, Cheng, & Hou, 2019). Hence, major rational targets for AD drug R&D have been (a) amyloid-beta itself via an immunotherapeutic approach, (b) amyloidogenic proteases, and (c) amyloid-beta catabolism. However, these ongoing approaches have not shown success in the clinic yet. In translational studies with mouse models, a newer approach targeting amyloid-beta oligomer has shown promise. In 6- to 7-month-old Tg SxFAD mice, injection of an Aβ oligomer-specific antibody rescued memory performance (Cline et al., 2018). Monomeric Aβ-binding peptide RD2, which renders Aβ unable to form oligomer, reversed AD symptoms (cognition, behavior, and Aβ plaque loads) in aged APP/PS1 mice, indicating its potential for therapeutic application (Schemmert et al., 2019).

In late-onset AD, amyloid-beta accumulation and senile plaque development begin in middle age. At the early stage, no immediate visible symptoms appear, and the time window is considered presymptomatic or latent. Ten to fifteen years later, neurofibrillary tangles begin to emerge. However, there is also a 3 to 5-year time window without notable memory or cognitive symptoms (Perrin, Fagan, & Holtzman, 2009). In a later stage of AD, memory/cognitive/behavioral symptoms and amyloid-beta plaques and neurofibrillary tangles are observed. Notably, plaques and tangles in the AD brain appear with differential localizations; plaques are diffusely distributed over the entire cortex, while tau tangles are seen in brain regions related to clinical symptoms and overlap with areas of hypometabolism (Dronse et al., 2017). As AD progresses, both lesions spread throughout the brain, each following a stereotyped pattern. Senile plaques spread from association cortices (Thal phase 1) to allocortical areas, including the hippocampus (Thal phase 2); then to diencephalic nuclei, striatum, and cholinergic nuclei of the basal forebrain areas (Thal phase 3); several brain stem nuclei (Thal phase 4); and cerebellum (Thal phase 5) (Thal, Rüb, Orantes, & Braak, 2002). Neurofibrillary tangles first appear in the entorhinal cortex (Braak stages I/II), then spread toward limbic structures, including the hippocampus (Braak stages III/IV) and association cortices (Braak stages V/VI) (Braak & Braak, 1991). Additionally, amyloid-beta accumulation around blood vessels, also known as cerebral amyloid angiopathy, appears.

Cerebral amyloid angiopathy may play a role in cognitive/behavioral symptoms via cerebrovascular system dysfunction (Weber, Patel, & Lutsep, 2018). This complex pathology led to a controversy regarding which pathology (amyloid-beta plaques, tau/p-tau tangles, or cerebral amyloid angiopathy) is more critical in AD symptoms and therefore represents a better therapeutic target. As the decades-long development of AD pathology is associated or concurrent with many biological events and general aging, it has been difficult to pinpoint an effective intervention or therapeutic target. As approaches targeting late-stage AD pathologies have not been successful, and as early amyloid-beta accumulation with oligomer formation has begun to be recognized as a critical step with the amyloid-beta oligomer hypothesis, the need to understand mechanisms leading to amyloid-beta accumulation is increasing.

3 | CURRENT AD DRUG RESEARCH AND DEVELOPMENT TARGETS

Mainstream AD drug research and development efforts have been directed toward (i) components directly involved in AD pathology, such as amyloid-beta or p-tau, amyloidogenic proteases, and other amyloid-beta or tau binding proteins, such as receptor for advanced glycation endproducts (RAGE); (ii) components associated with pathology and predicted to be involved in symptoms, such as neuroinflammation, oxidative stress, and mitochondrial dysfunction; and (iii) medicines that can ease cognitive/behavioral symptoms of AD, including neuronal function modulators and neurotransmitters, although they may be palliative and may not address pathological causes nor lead to fundamental cure.

As of 30 October 2019, the Clinicaltrials.gov database lists 2,214 clinical trials involved in AD (https://clinicaltrials.gov/). The Alzforum website, which maintains a database on potential dementia therapeutics, lists 216 therapeutic reagents for AD and mild cognitive impairment (MCI) (https://www.alzforum.org/therapeutics). However, only five reagents (donepezil, galantamine, memantine, rivastigmine, and tacrine) are approved by the US FDA for use as symptomatic relievers of AD, targeting the cholinergic system and other neurotransmitters. No other agent has been validated as a clinically effective target.

4 | INTRINSIC AND EXTRINSIC FACTORS THAT AFFECT AMYLOID-BETA AMOUNT

The earliest step of AD pathology development is cerebral accumulation of amyloid-beta, the mechanism of which has been elusive. A majority of sporadic AD patients do not carry mutation in familial AD genes (i.e., APP, PSEN1, or PSEN2) (Lanoiselée et al., 2017), suggesting that other drivers are involved in the development of sporadic late-onset AD cases. Here, we discuss amyloid-beta accumulation as a result of the disturbed balance between Aβ generation and catabolism (i.e., Aβ dyshomeostasis). Consistently, AD patients indicated impaired clearance rates for Aβ42 and Aβ40, compared with controls (Mawuenyega et al., 2010).

Various intrinsic factors can affect Aβ generation and/or catabolism. Amyloid-beta can be generated through intensive neuronal activity (i.e., activity-dependent Aβ generation) (Ovsepian & O’Leary, 2016). Activation of and/or increase in amyloidogenic proteases can play a role in increasing Aβ, as observed in patients with Down syndrome who exhibit early AD-like dementia and express a large amount of BACE1 (Miners, Morris, Love, & Kehoe, 2011). Systemic factors, such as the effect of oral and gut microbes on systemic inflammation, are also gathering interest (Tremlett, Bauer, Appel-Cresswell, Finlay, & Waubant, 2017). Sleep affects accumulation and removal of Aβ (Cordone, Annarumma, Rossini, & Gennaro, 2019). Reports indicate that Aβ catabolism decreases over age. Older mice showed a 40% decline in clearance of injected Aβ, which may be caused by a decline in the efficiency of exchange between the subarachnoid cerebrospinal
| Gene Name     | Full Name                          | Proposed function(s) and pathway(s) involved*                                                                 | "Cell cycle"/total publications** | "Mitosis"/total publications** | Reported involvement in cell cycle and/or mitosis (including possible link)                                                                 |
|---------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| ABCA7         | ATP-binding cassette subfamily A member 7 | Transporter, Lipid metabolism/homeostasis, Ceramide transport                                                | 2/228                            | 1/228                          | Ovarian cancer metastasis marker candidate (Elserova et al., 2017)                                                                 |
| ABI3          | ABI family member 3               | Inhibits ectopic metastasis of tumor cells and cell migration                                                | 13/406                           | 1/406                          | Tumor suppressor, Expression reduces growth and induces senescence (Latini et al., 2011)                                           |
| ACE           | Angiotensin I-converting enzyme    | Generates angiotensin II, a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance | 126/13779                        | 6/13779                        | Inhibition accelerates endothelial regrowth (Van Belle et al., 1997)                                                                |
| ADAM10        | ADAM metallopeptidase domain 10   | Metalloproteinase, Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form, Cleaves several other cell-surface proteins (e.g., ephrin-A2, CD44, CDH2, Notch) | 32/1364                          | 1/1364                         | Silencing inhibits the in vitro and in vivo growth of hepatocellular carcinoma cells (Liu, Zhang, Liu, Ji, & Wang, 2015), Constitutive activation promotes cell growth and activates the TNF-α/NFκB pathway in mantle cell lymphoma (Armanious, Gelebart, Anand, Belch, & Lai, 2011) |
| ADAMTS4       | ADAM metallopeptidase with thrombospondin type 1 motif 4 | ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover | 6/578                            | 0/578                          |                                                                                                                                 |
| ALPK2         | Alpha kinase 2                    | Kinase that recognizes phosphorylation sites in which the surrounding peptides have an alpha-helical conformation | 0/13                             | 0/13                           |                                                                                                                                 |
| APH1B         | Aph-1 homolog B, gamma-secretase subunit | Functional component of the gamma-secretase complex, which also contains presenilin and nicastrin, a subunit of APP protease complex | 1/37                             | 0/37                           |                                                                                                                                 |
| BIN1          | Bridging integrator 1             | Nucleocytoplasmic adaptor, synaptic vesicle endocytosis, cardiac muscle development                           | 35/413                           | 0/413                          | Tumor suppressor (Pan et al., 2012), A corepressor of the transcription factor E2F1, Inhibits cell cycle progression (Folk et al., 2019), Regulates fas/fas ligand-mediated apoptosis (Esmailzadeh, Huang, Su, Zhou, & Jiang, 2015), Accumulates adjacent to amyloid deposits in vivo (De Rossi et al., 2019) |
| BZR1P-1AS1    | BZR1P antisense RNA 1             | Noncoding RNA, Promoters and enhancers for TSPOAP1-AS1 gene                                                | 0/3                              | 0/3                            |                                                                                                                                 |
| CASS4         | Cas scaffold protein family member 4 | Docking protein that plays a role in tyrosine kinase-based signaling, related to cell adhesion and cell spreading | 3/25                             | 0/25                           |                                                                                                                                 |
| Gene Name | Full Name                                      | Proposed function(s) and pathway(s) involved* | "Cell cycle"/total publications** | "Mitosis"/total publications** | Reported involvement in cell cycle and/or mitosis (including possible link) |
|-----------|------------------------------------------------|-----------------------------------------------|-----------------------------------|--------------------------------|--------------------------------------------------------------------------|
| CD33      | CD33 molecule                                  | Lectin of the SIGLEC (Sialic-acid-binding immunoglobulin-like) family, cell–cell interaction, Transmembrane receptor expressed on cells of myeloid lineage | 241/3168                        | 4/3168                        | Marker for acute myeloid leukemia subtype, CD33 inhibition in myeloid cells causes apoptosis (Mingari, Vitale, Romagnani, Falco, & Moretta, 2001), Anti-CD33 antibody conjugates are being tested for CD33 + AML in clinic (Kobayashi et al., 2009). |
| CD2AP     | CD2-associated protein                          | Scaffolding molecule that regulates the actin cytoskeleton, receptor endocytosis, and cytokinesis | 17/403                          | 1/403                         | Involved in cytokinesis (Monzo et al., 2005)                              |
| CELF1     | CUGBP Elav-like family member 1                | May regulate pre-mRNA alternative splicing, mRNA editing, and translation; May be a specific regulator of miRNA biogenesis; Defects affect myotonic dystrophy via RNA toxicity | 21/234                          | 0/234                         | Upregulated in glioma, Promotes glioma cell proliferation by suppression of CDKN1B (Xia et al., 2015) |
| CLNK      | Cytokine-dependent hematopoietic cell linker   | Regulation of immunoreceptor signaling        | 0/22                            | 0/22                          |                                                                          |
| CLU       | Clusterin (aka. apolipoprotein J)              | A chaperon (secreted and cytosolic), Inhibits formation of amyloid fibrils, Involved in cell death, tumor progression, and neurodegenerative disorders | 119/1759                        | 7/1759                        | CLU OP activates PI3K/AKT pathway, overrides Cr(VI)-induced senescence in hepatocytes (Zhang, Zhang, Xiao, Zhong, and Xiao, 2019), CLU knockdown sensitizes cancer cells to chemotherapy drugs (Ai Nakouzi et al., 2016), Nuclear CLU is pro-apoptotic (Shannan, Seifert, Boothman, Tilgen, & Reichrath, 2006), Secretory CLU is pro-survival, High levels of sCLU caused G1 cell cycle arrest in distinct cell types (Yu & Tan, 2012) |
| CNTNAP2   | Contactin-associated protein-like 2            | Cell adhesion molecules and receptors in nervous system | 3/395                           | 0/395                         |                                                                          |
| CR1       | Complement C3b/C4b receptor 1                  | Membrane immune adherence receptor, Belongs to the receptors involved in complement activation, Captures and clears complement-opsonized pathogens by erythrocytes and monocytes/macrophage | 88/3263                        | 5/3263                        |                                                                          |
| DSG2      | Desmoglein 2                                   | Calcium-binding transmembrane glycoprotein components of desmosomes and cell–cell junctions | 13/310                          | 0/310                         | Overproduction is poor prognostic marker for HCC (Han et al., 2018), Knockdown arrests NSCLC cells via CDK2 decrease and p27 increase (Cai et al., 2017) |
| ECHDC3    | Enoyl-CoA hydratase domain-containing 3        | Fatty acid biosynthesis                       | 0/12                            | 0/12                          |                                                                          |
| Gene Name | Full Name | Proposed function(s) and pathway(s) involved* | "Cell cycle"/total publications** | "Mitosis"/total publications** | Reported involvement in cell cycle and/or mitosis (including possible link) |
|-----------|-----------|-----------------------------------------------|----------------------------------|-------------------------------|----------------------------------------------------------------------------------|
| EPHA1     | EPH receptor A1 | Ephrin receptor subfamily of the protein tyrosine kinase, Nervous system development, Contact-dependent bidirectional signaling into neighboring cells | 16/246                        | 1/246                        | Negative regulator of the Ras/MAPK pathway (Miao et al., 2001), exerts antimitogenic functions in a cell-type-specific manner, Knockdown of EPHA1 in ovarian cancer cells inhibited their aggressive traits |
| FERMT2    | Fermitin family member 2 | Scaffolding protein, Enhances integrin-mediated cell adhesion onto the extracellular matrix and cell spreading, Binds to membranes enriched in phosphoinositides, the assembly of focal adhesions | 4/64                        | 0/64                        | Inhibited by Wnt/beta-catenin, resulting in blockade of myoblast fusion in myoblasts (Suzuki, Pelikan, & Iwata, 2015) |
| HESX1     | HESX homeobox 1 | Conserved homeobox protein that is a transcriptional repressor in the developing forebrain and pituitary gland | 3/235                        | 0/235                       |                                                                                  |
| HLA-DRB5, HLA-DRB1 | Major histocompatibility complex, class II, DR beta 5, and DR beta 1 | Plays a central role in the immune system by presenting peptides derived from extracellular proteins | 0/464 (DRB5) | 0/464 (DRB5) |                                                                                  |
| INPP5D    | Inositol polyphosphate-5-phosphatase D | Hydrolyzes the 5' phosphate from phosphatidylinositol (3,4,5)-trisphosphate and inositol 1,3,4,5-tetakisphosphate, negatively regulating the PI3K (phosphoinositide 3-kinase) pathways, Negative regulator of myeloid cell proliferation and survival | 7/288                        | 0/288                        | Overexpression suppressed cell growth, migration, and invasion in vitro and in vivo in NSCLC via PI3K pathway inhibition (Fu et al., 2019) |
| KAT8      | Lysine acetyltransferase 8 | Histone acetylase (HAT), Chromatin architecture, Embryonic development | 32/145                        | 3/145                        | Important for cancer cell survival (Zhang, Liu, et al., 2013), Required for DNA damage response and double-strand break repair to ionizing radiation, RNAi for Rcd1, Rcd5, or MBD-R2 showed abnormal chromosome segregation in Drosophila (Pavlova et al., 2019) |
| Gene Name | Full Name | Proposed function(s) and pathway(s) involved | Cell/cycle/total publications** | Mitosis/total publications** | Reported involvement in cell cycle and/or mitosis (including possible link) |
|-----------|-----------|---------------------------------------------|---------------------------------|-----------------------------|--------------------------------------------------------------------------------|
| MEF2C | Myocyte enhancer factor 2C | MADS box transcription enhancer factor 2 (MEF2) family, Controls cardiac morphogenesis and myogenesis, Essential role in hippocampal-dependent learning and memory by suppressing the number of excitatory synapses and thus regulating basal and evoked synaptic transmission, Normal neuronal development | 65/1122 | 4/1122 | Regulates the expression of G2/M checkpoint genes (14-3-3, Gadd45b, and p21) and the subcellular localization of CYCLIN B1 (Badodi, Baruffaldi, Ganassi, Battini, & Molinari, 2015), Substrate of anaphase-promoting complex, Expression of phosphorylation mutant can delay cell cycle in colon cancer cells, Activates CDK inhibitor p21/CDKN1A and thus inhibits cell cycle transition (Di Giorgio, Gagliostro, Clocchiatti, & Brancolini, 2015), Acts as effectors of neurogenesis in the brain (Li et al., 2008), Drives B-cell receptor (BCR)-induced proliferation of mature B cells (Wilker et al., 2008) |
| MS4A6A | Membrane spanning 4-domains A6A, A4E | May be involved in signal transduction as a component of a multimeric receptor complex | 1/60 (MS4A6A) | 0/60 | |
| MS4A4E | Membrane spanning 4-domains A6A, A4E | May be involved in signal transduction as a component of a multimeric receptor complex | 1/26 (MS4A4E) | 0/26 | |
| NME8 | NME/NM23 family member 8 | Ciliary function, Sperm tail maturation | 0/31 | 0/31 | |
| NYAP1 | Neuronal tyrosine-phosphorylated phosphoinositide−3-kinase adaptor 1 | Regulates neuronal morphogenesis, Disruption in mice affects brain size and neurite elongation | 0/4 | 0/4 | |
| PTK2B/PYK2 | Protein tyrosine kinase 2 beta | Calcium-induced regulation of ion channels and activation of the map kinase signaling pathway, Member of the FAK subfamily of protein tyrosine kinases | 23/457 | 4/457 | Regulates actin cytoskeleton reorganization in fibroblasts (Du et al., 2001), p-PYK2 associates with the oocyte spindle and spindle poles, May function as a component of the microtubule-organizing center to regulate spindle assembly during the meiotic process of mouse oocytes (Meng et al., 2018), Promotes migration and invasion of glioma cells (Lipinski et al., 2005) |
| SCIMP | SLP adaptor and CSK interacting membrane protein | Transmembrane adapter/mediator, Major histocompatibility complex class II signal transduction, Immune synapse formation | 0/9 | 0/9 | |
| SLC24A4 | Solute carrier family 24 member 4 | Potassium-dependent sodium/calcium exchanger protein family, transporter | 0/84 | 0/84 | |
### TABLE 1 (Continued)

| Gene Name | Full Name | Proposed function(s) and pathway(s) involved* | "Cell cycle"/total publications** | "Mitosis"/total publications** | Reported involvement in cell cycle and/or mitosis (including possible link) |
|-----------|-----------|-----------------------------------------------|----------------------------------|--------------------------------|--------------------------------------------------------------------------------|
| SORL1     | Sortilin-related receptor 1              | Endocytosis and sorting, Transmembrane signaling receptor activity and low-density lipoprotein particle binding | 4/334                           | 2/334                          |                                                                                   |
| SPI1/PU.1 | Spi−1 proto-oncogene, hematopoietic transcription factor PU.1 | ETS-domain transcription factor that activates gene expression during myeloid and B-lymphoid cell development, Binds to the PU-box, a lymphoid-specific enhancer, Differentiation or activation of macrophages or B cells | 145/1961                       | 4/1961                         | PU.1 is essential for mixed-lineage leukemia (MLL) (Zhou et al., 2014), Required for the growth of MLL leukemic cells via the promotion of cell cycle progression and inhibition of apoptosis, Acts as tumor suppressor in myeloma (Ueno et al., 2017) |
| SUZ12P1   | SUZ12 pseudogene 1                        |                                                                                | 0/1                            | 0/1                            | Prostate cancer biomarker, Long noncoding RNA promoted the proliferation of and inhibited apoptosis of prostate cancer (Wan et al., 2016) |
| TREM2     | Triggering receptor expressed on myeloid cells 2 | Immune response, Membrane protein that forms a receptor signaling complex with the TYRO protein | 9/708                          | 0/708                          | Promotes microglial survival by activating the Wnt/β-catenin pathway (Zheng et al., 2017), TREM2/DAP12 complex regulates inflammatory responses in microglia via the JNK signaling pathway (Zhong et al., 2017), Overexpression enhances glioma cell proliferation and invasion (Wang et al., 2016), Acts as a tumor suppressor via Wnt1/β-catenin and Erk signaling in colorectal carcinoma (Kim et al., 2019) |
| ZCWPW1    | Zinc finger CW-type and PWWP domain-containing 1 | Function poorly known, A “bottleneck” gene                                      | 0/32                           | 0/32                           |                                                                                   |

*Based on GeneCards database.

**Publication numbers as of 5 November 2019, via PubMed keyword search.

Note: A list of 37 AD genetic risk loci (genes identified as frequently mutated in AD-omics studies) was used. The number of existing publications was examined for each gene, followed by a keyword search with "Gene X and cell cycle" or "Gene X and mitosis." The process provides an estimate for the current total research activity regarding the gene and for the gene's functional involvement in the cell cycle and/or in mitosis. Genes showing a direct or strong functional connection to the cell cycle and/or mitosis are marked in bold. Thirteen among the 37 AD genetic risk loci have indicated functions in the cell cycle and/or mitosis, suggesting the importance of the cell cycle and/or mitosis in AD development.
fluid and the brain parenchyma (Kress et al., 2014). Levels of nephrilysin, an Aβ-degrading protease, decreased with age in both normal and AD patients. This decreasing nephrilysin level may act as a trigger for AD (Hellsström-Lindahl, Ravid, & Nordberg, 2008). In APP-SL70 mice, the microglial response to increasing amyloid-beta was estimated to be overwhelmed with aging (Blume et al., 2018).

In addition to intrinsic factors, extrinsic or environmental factors can play a role. In a mouse model, recurrent activation of brain herpes simplex virus 1 (HSV1) infection led to amyloid-beta accumulation and other AD pathology (tau phosphorylation, neuroinflammation) (De Chiara et al., 2019), indicating that viral infection can trigger Aβ accumulation and AD pathology. In an AD-omics study, HHV-6A and HHV-7 were identified as prominently associated with AD among three independent cohorts (Readhead et al., 2018). Reports like these support the theory that pathogens trigger AD (Haas & Lathe, 2018; Itzhaki, 2014; Sochocka, Zwolińska, & Leszek, 2017), as well as the role of amyloid-beta as a protection mechanism against viral infection (Li, Liu, Zheng, & Huang, 2018). Although AD cannot be completely explained by the pathogen theory alone, pathogens may act as a risk factor or have an impact on a segment of patients with AD. A high rate of HSV1 and other infections was observed in AD patients (Sochocka et al., 2017). Since three subtypes of AD were identified based on the spread of neurofibrillary tangles (Murray et al., 2011), there may be more than one causal process, leading to distinct pathology of AD subtypes.

5 | A BRIEF HISTORY OF EARLIER STUDIES OF ANEUPLOIDY AND AD

Since the 1990s, a long-standing theory has purported that aneuploidy plays a critical role in AD development. In an early thesis noting AD-like dementia in patients with Down syndrome, Potter (1991) hypothesized that (i) aneuploidy (chromosome 21 trisomy) is causal to AD, and that (ii) genes associated with the risk of AD would be involved in the cell cycle, and such genes would lead to the development of aneuploidy when mutated (Potter, 1991). Following hypothesis (i), the link between aneuploidy and AD was explored using cytogenetics. Earlier studies tested the rate of aneuploidy in peripheral blood lymphocytes and fibroblasts from AD patients. Cells from familial and sporadic AD patients were shown to have more micronuclei than controls. The antifungal drug griseofulvin mitigated the increase in micronuclei in cells from patients with AD, indicating an altered response to genotoxic challenge (Petrozzi et al., 2002; Trippi et al., 2002). These results may be attributed to increased DNA damage and impaired DNA repair (Coppedè & Migliore, 2009), or perhaps to DNA replication stress (Yurov, Vorsanova, & Iourov, 2011). Newer studies indicated a higher aneuploidy rate in AD-affected neurons (Iourov, Vorsanova, Liehr, & Yurov, 2009). In addition, the presence of hyperploid neurons was noted (Arendt, Brückner, Mosch, & Löschke, 2010) [see Section 6.3 “High degree of aneuploidy in patients with AD and mild cognitive impairment (MCI)” for additional references]. Although a single-cell sequencing report noted conflicting results (van den Bos et al., 2016), and although reported rates of aneuploidy vary widely, collectively there seems to be solid support for increased aneuploidy in somatic cells and neurons of patients with AD. Supporting evidence for hypothesis (ii) includes reports that gene mutations causal to neurodegenerative diseases (APP, MAPT, PSEN for AD [see later sections]; Niemann–Pick C; Granic & Potter, 2013) also cause aneuploidy in neurons. In a later section, “Thirteen among 37 genes on the human AD genetic risk loci are functionally involved in the cell cycle and/or mitosis” (Table 1), we will discuss newer corroborating evidence from contemporary AD-omics.

In Boveri’s 19th-century theorem, aneuploidy was predicted to cause cancer (Boveri, 2008). Aneuploidy can be caused by external genotoxic challenges (e.g., radiation, chemicals, and virus) or by an internal defect in molecular mechanisms for genome maintenance that are intimately involved in cell cycle regulations. Mainstream mechanistic studies of the cell cycle emerged rather independently from studies of AD. The conceptual framework that the cell cycle is driven by cyclin-dependent kinases (CDKs) and cyclins emerged by the mid-1980s/early 1990s (Nurse, 2012). During the same period, major cell cycle driving enzymes and their regulatory components were identified through combined efforts, including genetics work using budding yeast S. cerevisiae, fusion yeast S. pombe, fungi A. nidulans, and fruit fly D. melanogaster; biochemistry studies using egg extracts of frog X. laevis; and cell biology studies with cultured cells (see Murray & Hunt, 1993).

Cancer, carcinogenesis, and developmental defects associated with aneuploidy have been the primary disease targets of cell cycle studies. These types of investigations were assumed to be useful for finding methods and targets to manipulate cell cycle and cell growth, which could lead researchers to cancer therapeutics. Over the years, this assumption has been shown to be correct. Many validated cancer therapeutics target machineries that are involved in the cell cycle. In the 1990s–2000s, aneuploidy-inducing transgenic genomic instability mouse models, such as chromosome instability (CIN) models and microsatellite instability (MIN) models, were developed. The models were used mainly to assess cancer development (Rao & Yamada, 2013; Rao, Yamada, Yao, & Dai, 2009; Simon, Bakker, & Fojer, 2015) and to examine the relationship between aneuploidy and carcinogenesis (Weaver & Cleveland, 2009; Zasadil et al., 2016). However, most cancer assessment studies do not keep mice until old age. It was only recently that experimental results testing the link between genomic instability and AD in aged mouse models started to be reported (Rao, Farooqui, Asch, & Yamada, 2018).

6 | THE “AMYLOID-BETA ACCUMULATION CYCLE”

From the notion that aneuploidy plays a role in AD development, some hypotheses focusing on the role of mitotic cycle re-entry of neurons...
evolved. One such hypothesis was the “two-hit hypothesis” that proposes age and mitotic re-entry as two key factors (“hits”) for AD development (Webber et al., 2005; Zhu, Lee, Perry, & Smith, 2007; Zhu, Raina, Perry, & Smith, 2004). Based on results from genomic instability mouse models, we proposed a version of the two-hit hypothesis with an emphasis on the role of prolonged mitosis in accumulating amyloid-beta, the “three-hit hypothesis.” The “three-hit hypothesis” proposes (I) aging, (II) mitotic re-entry, and (III) prolonged mitosis as three key factors for the development of AD (Rao, Farooqui, Zhang, Asch, & Yamada, 2018). Recent literature led us to an integrative hypothesis, the “amyloid-beta accumulation cycle,” incorporating interference in mitosis and the aneuploidogenic role of amyloid-beta (Figure 2). The rationales for the “amyloid-beta accumulation cycle” are summarized below.

### 6.1 Neuronal cell cycle re-entry occurs in AD

Normally, neurons are terminally differentiated cells and remain in the G0 quiescent state. However, human AD brains show signs of neurons in the mitotic cycle and poly(tetra)ploid 4N cells (Herrup, 2010; Herrup & Arendt, 2002; Herrup, Neve, Ackerman, & Copani, 2004; Neve & McPhie, 2006). Consistently, human AD brains show misregulations in canonical cell cycle driving proteins (e.g., CDC25 phosphatases) and inhibitory proteins (e.g., wee1 kinase) in the direction toward mitosis; in inhibitory proteins (e.g., wee1 kinase) in the direction toward mitosis; in the mitotic cycle and poly(tetra)ploid 4N cells (Herrup, 2010; Herrup & Arendt, 2002; Herrup, Neve, Ackerman, & Copani, 2004; Neve & McPhie, 2006). Consistently, human AD brains show misregulations in canonical cell cycle driving proteins (e.g., CDC25 phosphatases) and inhibitory proteins (e.g., wee1 kinase) in the direction toward mitosis; in

### 6.2 Various mitogenic/growth signaling factors are activated in the AD brain

Consistent with Section 6.1, misregulations in various mitogenic/growth signaling factors, including ERK/MAPK, GSK3, PI3K/AKT, and CDK, are reported in the AD brain (Kirouac, Rajic, Cribbs, & Arendt, 2002; Herrup, Neve, Ackerman, & Copani, 2004; Neve & McPhie, 2006). Various mitogenic/growth signaling factors are activated in the AD brain (Kirouac, Rajic, Cribbs, & Arendt, 2002; Herrup, Neve, Ackerman, & Copani, 2004; Neve & McPhie, 2006).
(a) "Amyloid-beta (Aβ) accumulation cycle"

Neurotoxic Aβ: Triggers stress responses, inflammation, mitogenic signaling

Neuron (or glial/stem cell)

Mitogenic signal

Pathogen AD Mutation

Attempt mitosis (Tetraploid) Phospho-H3+

"Stuck" in mitosis (prolonged mitosis) Accumulate Aβ, p-tau, BACE

Cell death (Mitotic catastrophe)

May attack surrounding cells May function as "Aβ seeds"

(b) The "Amyloid-beta accumulation cycle" as an update of the Three-hit hypothesis

The "Two-hit hypothesis"
1. Age
2. Mitotic re-entry

(Zhu et al., 2004/2007)

The "Three-hit hypothesis"
1. Age
2. Mitotic re-entry
3. Mitotic prolongation

(Rao et al., 2018b)

Amyloid-beta accumulation cycle

1. Mitogenic signaling and mitotic re-entry
2. "Stuck in mitosis"; accumulation of Aβ, p-TAU, and BACE during the prolonged mitotic state
3. Cell death (Mitotic catastrophe)
4. Release of Aβ to extracellular matrix
5. Aβ provokes mitogenic signaling
6. Aβ causes mitotic errors/"stuck in mitosis" state and aneuploidy

(c) Cerebral amyloid-beta protein can accumulate in mice with an unmodified APP gene.

(i) Spontaneous accumulation of Aβ in aged Sgo1−/−

Cortex

Hippocampus

(ii) Aβ in HSV1-infected C57BL/6 (wild-type)

Cortex

Hippocampus
Amyloid-beta oligomers are primarily achieved through glial cells, especially \textit{(Bhaskar et al., 2014).} The expression and release of pro-inflammatory molecules is increased in the cell cycle toward mitosis, followed by neuronal cell death \textit{(sTREM)}, a marker of microglial inflammatory reaction (monocyte chemoattractant protein-1 (MCP-1)), and astroglial activation marker (chitinase-3-like protein 1 (YKL-40)) increased as AD progression \textit{(Nordengen et al., 2019).}

**6.3 | High degree of aneuploidy in patients with AD and mild cognitive impairment (MCI)**

Human brains are naturally aneuploidogenic during early development and carry a higher rate of aneuploid cells in adulthood. However, compared with healthy subjects, patients with both familial/early-onset and sporadic late-onset AD show widespread aneuploidy in their brains and in peripheral blood cells \textit{(Bajic, Spremo-Potparevic, Zivkovic, Isenovic, & Arendt, 2015; Hou, Song, Croteau, Akbari, & Bohr, 2017; Iourov et al., 2009; Lee, Thomas, & Fenech, 2015; Zivković et al., 2010).} This AD-associated aneuploidy is thought to be due to genomic instability \textit{(Andriani, Vijg, & Montagna, 2017; Shepherd, Yang, & Halliday, 2018).} This observation suggests the existence of a cell population that has newly entered a flawed cell cycle in patients with AD.

**6.4 | Aneuploidy can cause intellectual disability and/or general aging**

Many individuals with congenital aneuploidy or aneuploidogenic conditions show symptoms of intellectual disability, suggesting a role of genomic stability in maintaining neuronal and higher cognitive/behavioral functions. Down syndrome (DS) is caused by developmental aneuploidy/chromosome 21 trisomy. DS patients develop early-onset AD-like dementia in their 40s-50s \textit{(Lott & Head, 1999; Potter, 1991).} The conventional interpretation of the AD-like dementia in DS patients is that it is due to the APP gene on chromosome 21; triplicate copies of the APP gene facilitate amyloid-beta accumulation and development of AD in DS patients. Yet, aneuploidy can also produce proteotoxic effects and ER stress, and disturb stoichiometry of macromolecular complexes \textit{(Brennan et al., 2019; Chunduri & Storchová, 2019),} as well as transcriptional alterations at the cellular and/or organ level, compared with those of nonaneuploid control subjects \textit{(Wangsa et al., 2019).} Thus, the general effects of aneuploidy at the cellular and organ levels may contribute to AD development, in addition to APP overproduction in patients with DS. A recent report on a mouse model of triplication of chromosome 21 genes other than APP supports the presence of an effect of aneuploidy on amyloid-beta accumulation. The mice showed increased amyloid-beta aggregation and deposition of plaques with cognitive deficits, although they showed no increase in APP abundance \textit{(Wiseman et al., 2018).}

Cohesinopathy, a defect leading to premature mitotic chromosome segregation and chromosome instability, is an aneuploidogenic condition. Congenital mutations causing cohesinopathy in humans result in conditions with intellectual disability, deformity, and proneness to cancers, such as Cornelia de Lange syndrome and Roberts syndrome \textit{(Cucco & Musio, 2016; Zhu & Wang, 2019).} Other aneuploidogenic conditions include mosaic variegated aneuploidy syndrome, which is caused by a mutation in (a) a mitotic checkpoint component BubR1/Bub1B (type 1); (b) CEP57, which encodes a centrosomal protein (type 2) \textit{(Snape et al., 2011);} or (c) TRIP13, which is involved in mitotic checkpoint complex silencing via Mad2 liberation \textit{(Alfieri, Chang, & Barford, 2018; Kaisari et al., 2019).} A reduction in BubR1 protein in mice \textit{(BubR1\textsuperscript{14H} mice)} resulted in a systemic and neuronal progeria condition \textit{(Choi et al., 2016) and in impairment of adult hippocampal neurogenesis \textit{(Yang et al., 2017).} The progeric conditions were partly ameliorated by targeted elimination/reduction of p16\textsuperscript{INK4}-positive cells \textit{(Baker et al., 2011,} by enhancing Wnt signaling via loss of Dickkopf-1 \textit{(Seib et al., 2013) or via inhibition of secreted frizzled-related protein 3 (sFRP3) \textit{(Cho et al., 2019),} both of which are endogenous Wnt antagonists. These findings suggest that (a) there is a role of genomic maintenance and aneuploidy in aging processes, and that (b) cell proliferation in the hippocampus is controlled by Wnt signaling. This hippocampal defect may affect neurocognitive performance.
et al., 2019). However, the stage at which APP is converted to amyloid-beta is a question that is addressed less often. APP can be phosphorylated by multiple kinases, including cdk2, Rho-associated coiled-coil kinase 1 (ROCK1), and Polo-like kinase 2 (Plk2). The phosphorylation affects its proteolytic processing, trafficking, and protein–protein interaction (Muresan & Muresan, 2007; Suzuki & Nakaya, 2008; Vieira, Rebeiro, Domingues, da Cruz e Silva, & da Cruz e Silva, 2009). Inhibition of Plk2 reduced Aβ formation, synapse loss, and memory decline in the APP-swDI AD mouse model (Lee et al., 2019). APP is phosphorylated at Thr668, which occurs during mitosis through mitotic cdc2 kinase (Suzuki et al., 1994). Thr668-phosphorylated APP was associated with the centrosome (Judge, Hornbeck, Potter, & Padmanabhan, 2011). Lack of APP resulted in delayed G2/mitosis in APP-/— mice (López-Sánchez, Müller, & Frade, 2005), suggesting a role of APP during mitosis. Moreover, amyloid-beta generation was increased during mitosis in cycling cultured H4-15X cells and with antimitotic drug treatments, suggesting that mitotic cells are a source of amyloid-beta (Judge et al., 2011). Conversely, amyloid-beta can interfere with mitosis by disrupting mitotic spindles and inhibiting mitotic motors (Borysov, Granic, Padmanabhan, Walczak, & Poter, 2011), suggesting that amyloid-beta accumulation alone can be aneuploidogenic. Amyloid-beta oligomers are mitogenic and can trigger the cell cycle (Varvel et al., 2008). Thus, amyloid-beta accumulation and the aneuploidogenic mitotic state may form an “amyloid-beta accumulation cycle” (Figure 2a).

Tau: Human neurofibrillary tangles co-localized with MP2 antisigns, a mitotic marker. The report suggests the involvement of mitosis in generation of tangles (Kondratick & Vantré, 1996). Human neuroblastoma SY5Y cells overexpressing tau provide a model for taurpathy studies. Abnormal tau phosphorylation of the Alzheimer-type (AT100 immunopositive and Ser242) was observed in these cells during mitosis (Delobel et al., 2002). G2/M blockers (paclitaxel, vinblastine, and vincristine) have a dose-dependent effect on tau phosphorylation at Ser-202 and Ser-396/404 in N2A-Tau3R cells. The Ser-201 and Ser-396/404 phosphorylation on tau are associated with neurofibrillary tangles (Conejero-Goldberg, Townsend, & Davies, 2008). During mitosis, c-Jun N-terminal kinase phosphorylates R406W tau (Tatebayashi et al., 2006). Taken together, these results indicate that mitotic conditions can generate phosphorylated tau, which is associated with neurofibrillary tangles (Pope et al., 1994; Preuss & Mandelkow, 1998; Vincent, Zheng, Dickson, Kress, & Davies, 1998).

6.6 | Mutations associated with familial/early-onset AD can cause mitotic error and aneuploidy, as well as other cell cycle disturbances

Presenilin 1/PSEN1 mutation (e.g., familial AD mutation in presenilin 1 [M146L and M146V]) is linked to familial/early-onset AD. Overexpression of mutant PSEN1 caused chromosome missegregation and aneuploidy in vivo (mice) and in vitro, with mitotic spindle defects observed (Boeras et al., 2008). PSEN1 P117R mutation is a pathogenic AD mutation that can cause increases in p53 and p21 proteins, G1 phase prolongation, S phase shortening, and decreased apoptosis in human lymphocytes (Bialopirowicz et al., 2012). Lymphocytes are proposed to serve as a surrogate indicator for the development of AD, as these cells are responsive to oxidative stress and other challenges, and are indicative of aneuploidy and cell cycle disturbances that mirror the condition of neurons in patients with AD (Wojsiat, Prandelli, Laskowska-Kaszub, Martín-Reqüero, & Wojda, 2015). As mentioned in Section 6.5, amyloid-beta can also disrupt the mitotic spindle and inhibit mitotic motors, thus causing mitotic defects and aneuploidy (Borysov et al., 2011). The APOE subtype is associated with AD risk. Knockdown of APOE in APOE-expressing ovarian cancer cells led to G2 cell cycle arrest and apoptosis, suggesting its context-dependent role in cell cycle progression (Chen et al., 2005).

6.7 | Forced cell cycle re-entry resulted in amyloid-beta and p-tau accumulation in mouse brains

Transgenic mice in which cell cycle reactivation in neurons is forced by SV40 T antigen via the tet-on/off system show signs of mitotic re-entry (e.g., PCNA, cyclin B1, MPMA2) and Aβ deposits and phosphorylated tau in the brain (Park, Hallows, Chakrabarty, Davies, & Vincent, 2007). Expression of SV40 T antigen causes replication stress, mitotic dysfunction, and aneuploidy (Hu, Filippakis, Huang, Yen, & Gjerdup, 2013), suggesting a link among mitotic re-entry, aneuploidy, and AD pathology.

6.8 | Amyloid-beta can bind to mitotic motors and microtubules, causing mitotic error and aneuploidy, as well as triggering the stress response

Amyloid-beta can disrupt the mitotic spindle and inhibit mitotic motors (e.g., Eg5, KIF4A, MCAK), causing mitotic defects with prolonged mitosis and aneuploidy (Borysov et al., 2011). The transcriptome of cultured SH-SY5Y cells expressing P301L tau was most affected in the cell cycle and cell proliferation; proteomic analysis on an amyloid-beta (1-42)-injected mouse model revealed that the stress response and metabolism pathways were most affected (Götz et al., 2008). Amyloid-beta injection in a rat model caused pro-apoptotic changes (increased caspase-3, decreased Bcl2/Bax ratio) and activation of stress/mitogenic signaling (increased pERK, pJNK, and NFKB65kd; decreased iKB) (e.g., Dong, Ji, Han, & Han, 2019). Thus, once accumulated, amyloid-beta can be aneuploidogenic by itself and can trigger stress response and cell death.

6.9 | Infection with AD-associated pathogens can cause mitotic re-entry, mitotic errors, and/or prolonged mitosis

Various pathogens, including viruses (HHV1-6, HCV), bacteria (Chlamydia pneumoniae, Helicobacter pylori), fungi (Candida albicans),
mitotic re-entry, mitotic errors, and/or prolonged mitosis may help
and by conditioned medium in vitro (Lavine & Arrizabalaga, 2009).

- macrophages to fail cell division, leading to large multinuclear ane
axis (Umeda et al., 2009). Phagocytosed phase and chromosomal segregation errors with abnormal division

**7 | WILL ANEUPLOIDY ALONE BE SUFFICIENT TO CAUSE AMYLOID-BETA ACCUMULATION?**

Cohesinopathy–genomic instability model Shugoshin 1 (Sgo1) haploinsufficient mice (Sgo1−/− mice) showed spontaneous cerebral am

Amyloidogenic protease BACE and mitotic marker phosphor-histone H3 co-localized with amyloid-beta in amyloid-beta-expressing cells, suggesting that mitotic/quasi-mitotic/mitotic catastrophe cells were responsible for increased amyloid-beta in aged Sgo1−/− mice (Rao, Farooqui, Zhang et al., 2018).

However, spindle checkpoint defect–genomic instability model BubR1−/− mice did not show cerebral amyloid-beta accumulation (Rao, Farooqui, Zhang et al., 2018), suggesting that aneuploidy alone may not be sufficient to cause amyloid-beta accumulation in a mouse model. Since a major difference in these two chromosome instability–aneuploidogenic models is spindle checkpoint function and prolonged mitosis, prolonged mitosis was proposed to be one of the three critical factors (the "three-hit" hypothesis; Figure 2b) for amyloid-beta accumulation (Rao, Farooqui, Asch et al., 2018). Thus, types of aneuploidy that are accompanied by prolonged mitosis, such as cohesinopathy and amyloid-beta poisoning, are speculated to further lead to amyloid-beta accumulation.

Whether tetraploidization, another type of aneuploidy, contributes to AD development is a matter of controversy. Tetraploidization was reported to occur in normal and AD brains to a similar degree (Westra, Barral, & Chun, 2009). This finding suggests that the effects of tetraploidization on AD development are limited. A newer paper, however, reported a correlation between neuronal tetraploidization in the cerebral cortex in mice and reduced cognition and AD-associated neuropathology, suggesting a causal role of tetraploidization in the development of AD (López-Sánchez et al., 2017). For the tetraploidization mechanism, as AD brains abundantly express neurotrophin receptor p75NTR and proNGF (nerve growth factor), their involvement in triggering neuronal tetraploidization, subsequent abortive mitosis, cell death, and hence neurodegeneration was suggested (Frade & López-Sánchez, 2010). Determining the cause–consequence relationship of tetraploidization in AD may not be simple, as they may occur rather simultaneously.
CLNK, TREM2, CNTAP2, APH1B, KAT8, SCIMP, ABI3, SUZ12P1, ALPK2, and BZRAP-AS1 were identified with international transethnic cohorts (Jun et al., 2017) (Table 1).

Using genome-wide association studies (GWASs), Han, Huang, Gao, and Huang (2017) identified functions of the genes and categorized these functions as "regulation of beta-amyloid formation," "regulation of neurofibrillary tangle assembly," "leukocyte-mediated immunity," and "protein-lipid complex assembly" signaling pathways. With the protein–protein interaction network and functional module analyses, they also identified "hub" genes and "bottleneck" genes indicating three subnetworks. The hub genes included APOE, PICALM, BIN1, ABCA7, CD2AP, CLU, CR1, MS4A4E, and MS4A6A, while the bottleneck genes included APOE, TOMM40, NME8, PICALM, CD2AP, ZCWPW1, FAM180B, GAB2, and PTK2B (Han et al., 2017). However, as of 2019, not all genes are well characterized, as indicated by the limited number of publications listed in Table 1.

From supporting evidence of the involvement of the cell cycle and mitotic re-entry in AD development, we hypothesized that some of the genes identified as AD genetic risk loci are functionally involved in the cell cycle and/or mitosis. We performed a series of literature searches using "cell cycle" or "mitosis" as keywords for each of the genes. The search revealed possible functional involvement in the cell cycle or mitosis regulation for 13 among 37 genes (Table 1). This result provides additional support to the long-standing hypothesis that human AD development is associated with, influenced by, or caused by misregulations in the cell cycle or mitosis via gene mutations, at least in part. The hypothesis warrants further investigation.

9 | EFFECTS OF CELL CYCLE INTERFERING DRUGS ON AD MODELS

The aforementioned reports suggest that two major AD pathological features, plaques and tangles, are caused by or associated with cell cycle misregulation toward mitosis. Existing pharmacological reagents can interfere with the cell cycle and its machineries, leading to the question of whether these drugs affect neuronal health and AD symptoms and pathology.

9.1 | Antimitotic drugs can be neuroprotective against tauopathy

With exceptions of mitotic kinase or mitotic motor inhibitors, most antimitotic drugs target microtubule dynamics and mitotic spindles. Taxanes, including paclitaxel/Taxol, are microtubule stabilizers, while vinblastine and vincristine are microtubule destabilizers. Both classes of antimitotic drugs have a demonstrated history of use in cancer chemotherapy (Florian & Mitchison, 2016). Numerous in vitro results suggest the benefits of antimitotics for tauopathy. For example, cultured Aplysia neurons expressing mutant–human–tau indicate morphological signs of neurodegeneration under live confocal imaging platforms. A clinically relevant dose of 10 nM paclitaxel rescued these effects, whereas 100 nM paclitaxel facilitated them (Shemesh & Spira, 2011). In testing drugs in animal models, blood–brain barrier penetration and cerebral drug availability must also be considered (Brunden et al., 2011). In the PS19 tau transgenic mouse model of tauopathy, the brain-penetrant antimitotic drug epothilone D reduced the burden of tau pathology (Zhang et al., 2012). Another brain-penetrant microtubule stabilizer, dictyostatin, also produced improvement in CNS/brain measures (Brunden, Lee, Smith, Trojanowski, & Ballatore, 2017; Makani et al., 2016). Note that most antimitotics target microtubule dynamics. The possibility remains that their neuroprotective effects occur through microtubule and microtubule-binding protein-mediated signaling and/or axonal transport, rather than cell cycle effects (Brunden et al., 2017; Trojanowski, Smith, Huryn, & Lee, 2005). There are ongoing translational studies and clinical trials. For example, TPI-287/aboeptaxane is a brain-penetrant microtubule stabilizer that indicated efficacy in PS19 tau transgenic mice. Recent basket clinical trials on different tauopathies to test the safety, tolerability, and potential efficacy of TPI-287 infusion indicated that (i) TPI-287 was generally well tolerated, although anaphylactoid reactions occurred in 3/26 of AD patients, but not in 42 4-repeat tauopathies (4RT) patients, which led to a discussion of a potential difference in sensitivity profiles of AD and 4RT patients; (ii) CSF YKL-40 level changed in TPI-287 groups; and (iii) the AD treatment group showed a smaller decline in MMSE scores than did the placebo group, although the difference was not significant (Tsai et al., 2019). Still, antimitotics remain candidate drugs for AD management.

9.2 | CDK inhibitors ameliorated AD symptoms in animal AD models

CDK5 is a unique member of the CDK family. Unlike canonical cell cycle driving CDKs, such as CDK1 and CDK2, Cdk5 is inactive in the cell cycle, but is specifically expressed and predominantly active in postmitotic neurons. Its role in AD has long been postulated (Dhavan & Thai, 2001). In physiological conditions, CDK5 binds with its activator, p35, and plays roles in the development of CNS and movements of neurons. However, once neurons experience pathogenic challenges, Cdk5 associates with p25, which is generated from p35 by calpain-dependent cleavage, and becomes hyperactivated. CDK5/p25 causes aberrant hyperphosphorylation of various substrates that include APP, tau, and neurofilaments. Subsequently, Aβ formation, tau hyperphosphorylation, synaptic plasticity, oxidative stress, and mitochondrial dysfunction occur, followed by neuronal cell apoptosis and neurodegeneration with AD pathology (Liu et al., 2016; Lopes & Agostinho, 2011). CDK5 is also a regulator of other cell cycle regulators, including c-Jun and p38MAPK (Chang et al., 2010). Misregulation of CDK5 can trigger aberrant activation of cell cycle kinases and phosphatases, leading to neuronal cell death (Chang, Vincent, & Shah, 2012). CDK5 inhibition has a neuroprotective effect (Mushtaq et al., 2016). Diaminohexaloses is a CDK5 and GSK3β inhibitor. Diaminohexaloses decreased PHF-1 immunoreactivity in two animal models of AD
Flavopiridol/Alvocidib is a potent and specific inhibitor of CDKs 1, 2, 4, and 7 in vitro, showing a clear blockade of cell cycle progression at the G1/S and G2/M boundaries (Senderowicz, 1999). In the hCOX-2 transgenic mice, overexpression of human COX-2 in murine primary hippocampal neurons accelerated beta-amyloid-mediated apoptosis. The in vitro neuronal damage was prevented by flavopiridol (Xiang et al., 2002). Leggio et al. (2016) tested flavopiridol/Alvocidib in an amyloid-beta-injected AD mouse model. ApoE injected mice showed mitotic cyclin A-positive cycling neurons in the frontal cortex and the hippocampus, and displayed memory deficits. The cell cycle events and memory deficits were prevented by flavopiridol administered at 0.5 and 1 mg/kg body weight. Zhang, Gaiteri, et al. (2013), reported that (a) a strong association with AD clinical and pathological traits and cell cycle-enriched module/subnetwork, and (b) the cell cycle-enriched module/subnetwork showed the second largest loss of gene–gene interactions in AD compared with normal controls, thus was among the most affected. Huang et al. (2019) predicted that denticleless (DTL) is the key driver gene of the cell cycle-enriched module and investigated the role of DTL-encoded CDT2 protein in AD pathology. In addition, CDT2 is a part of the cell cycle-driving CUL4 CRL ubiquitin ligase complex. They reported upregulation of DTL/CDT2 in human patients with AD and increased degradation of p21, a CDK inhibitor protein, in vitro with CDT2 overexpression. In mice overexpressing CDT2, degradation of p21 released CDKs’ activity toward cell cycle progression and triggered AD processes, including increases in amyloid-beta, p-tau, and BACE; memory deficits; and a gene expression signature similar to that observed in human AD, for example, increases in APOE, CASS4, and CLU. Treatment with CDK2/7/9 inhibitor roscovitine/selicilic rescued CDT2-induced cognitive defects in CDT2-overexpressing mice (Huang et al., 2019).

9.3 Targeting mitogenic signaling

Mitogenic signaling is another potential target for AD drugs. However, few clinical trials for AD have explored mitogenic signaling. Those trials included examinations of the following drugs: lactoferrin, which can modulate p-AKT/PTEN (Mohamed, Salama, & Schaal, 2019); neflmapimoid, a specific inhibitor of p38MAPK-alpha (Alam, Blackburn, & Patrick, 2017); bryostatin 1, an activator of protein kinase C epsilon (Nelson et al., 2017); tideglsusib, an inhibitor of GSK3 (Lovestone et al., 2015); and lithium, a GSK3 inhibitor (Forlenza et al., 2011). Although this “targeting mitogenic kinase/signaling” approach has not become mainstream in AD research and drug development, the approach has been established in cancer research and drug development, with success against oncogene-addicted cancers (e.g., imatinib/Gleevec targeting Bcr-Abl tyrosine kinase, trastuzumab/Herceptin targeting Neu receptor). Due to organ-specific issues (e.g., blood–brain barrier [BBB]-mediated drug delivery), cancer drug repurposing for AD therapy may not be straightforward. Still, given the abundance of accumulated resources for targeting mitogenic signaling, the approach may hold great future potential.

10 CONCERNS TO BE ADDRESSED

Cancer treatments can leave cognitive impairment in a segment of cancer patients during the course of treatment or after completion, a phenomenon known as chemobrain (Argyriou, Assimakopoulos, Ionomou, Giannakopoulou, & Kalofonos, 2011). A meta-analysis of animal model studies indicated a correlation between cognitive decline and chemotherapy drug treatments, especially with the cisplatin, CMF (cyclophosphamide, methotrexate, fluorouracil combination), and MTX (methotrexate) + 5-FU chemotherapy regimens (Matsos & Johnston, 2019). However, there is currently little evidence that the treatments caused amyloid-beta accumulation or triggered AD-like dementia. Instead, the cognitive decline is attributed to damage to the BBB, oxidative stress, and cytokine dysregulation; thus, this chemobrain phenomenon is believed to be mechanistically closer to vascular dementia (Ren et al., 2019; Ren, St Clair, & Butterfield, 2017). Consistently, severe chemobrain is associated with cytotoxic DNA-damaging drugs, rather than CDK inhibitors. An inverse relationship between cancer and AD is known; that is, cancer survivors have less likelihood of developing AD (Zhang et al., 2015). The inverse relationship is proposed to be related to a balance in cellular tendencies toward cell death or growth (Shafi, 2016). Mechanisms in cell survival/death regulation, that is, p53, Pin1, and the Wnt signaling pathway, were discussed as potential therapeutic manipulation targets (Behrens, London, & Roe, 2009). In addition to innate cellular tendencies, we speculate that the inverse relationship may be in part due to a therapeutic or intervention effect of cancer chemotherapy drug on preclinical AD. When cell cycle-managing chemotherapy drugs are to be repurposed for AD prevention and/or therapy, we suggest designing clinical trials with careful and conservative dosing, with a less likelihood of BBB damage and/or chemobrain induction.

11 SUMMARY

Increasing evidence, including recent -omics data from human patients with AD, points to a critical role of the cell cycle and mitosis, leading to the “amyloid-beta accumulation cycle,” in the development of AD pathology. CDK inhibitors tested on animal models of AD showed symptomatic relief, corroborating the notion that the cell cycle and mitosis are targets of AD drug research and development. With further support, existing cell cycle and mitosis-targeting drugs, many of which are clinically used as cancer drugs, may be successfully repurposed as AD drugs in the near future.
ACKNOWLEDGEMENTS

We thank Ms. Kathy Kyler for editorial aid, and Ms. Taylor McCoy and Ms. Elizabeth Cambron for administrative aid. Special thanks to anonymous reviewers for the journal. This work was supported by grants from the U.S. National Institutes of Health to C.V. Rao (NCI R01CA094962; NCI R01CA213987) and research funds from the Stephenson Cancer Center to H.Y. Yamada.

CONFLICTS OF INTEREST

No conflicts of interest declared.

AUTHOR CONTRIBUTIONS

H.Y. Yamada contributed all aspects of the project. C.V. Rao and A.S. Asch provided intellectual input and material support. D.J.J. Carr contributed generation of unpublished key data.

ORCID

Hiroshi Y. Yamada https://orcid.org/0000-0002-0536-5581

REFERENCES

Akiyama, H., Mendes, R., Fazio, D., Barger, J., Park, J., et al. (2011). Alzheimer’s disease pathology in aneuploid brain: a tale of genome instability. *Neuroscience and Biobehavioral Reviews*, 35, 1901–1910. https://doi.org/10.1016/j.neubiorev.2011.08.001

Bajic, V., Spremo-Potparevic, B., Zivkovic, L., Isenovic, E. R., & Arendt, T. (2015). Cohesion and the aneuploid phenotype in Alzheimer’s disease: A tale of genome instability. *Neuroscience and Biobehavioral Reviews*, 55, 365–374. https://doi.org/10.1016/j.neubiorev.2015.05.010

Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., et al. (2011). Clearance of p16Ink4a-positive senescent cells delays age-related disorders. *Nature*, 479, 232–236. https://doi.org/10.1038/nature10600

Beecham, G. W., Hamilton, K., Naj, A. C., Martin, E. R., Huentelman, M., Myers, A. J., et al. Montine, T. J. (2014). Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. *PLoS Genetics*, 10, e1004606. https://doi.org/10.1371/journal.pgen.1004606

Behrens, M. I., Lendon, C. L., & Roe, C. M. (2009). A common biological mechanism in cancer and Alzheimer’s disease? *Current Alzheimer Research*, 6, 196–204.

Belkhefia, M., Rafa, H., Medjeber, O., Behairi, N., Abada-Bendib, M., Touil-Boukoffa, C. (2014). IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: A study in Algerian patients. *Journal of Interferon and Cytokine Research*, 34, 839–847. https://doi.org/10.1089/jir.2013.0085

Bhaskar, K., Maphis, N., Xu, G., Varvel, N. H., Kokiko-Cocharan, O., Weick, J. P., et al. Lamb, B. T. (2014). Microglial derived tumor necrosis factor-α drives Alzheimer’s disease-related neuronal cell cycle events. *Neurobiology of Diseases*, 62, 273–285. https://doi.org/10.1016/j.nbd.2013.10.007

Bialopiotrowicz, E., Szybinska, A., Kuzniecka, B., Buizza, L., Uberti, D., Kuznicki, J., & Wojda, U. (2012). Highly pathogenic Alzheimer’s disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes. *Journal of Alzheimer’s Disease*, 32, 397–415. https://doi.org/10.3233/JAD-2012-121129

Blume, T., Focke, C., Peters, F., Deussing, M., Albert, N. L., Lindner, S., et al. Brendel, M. (2018). Microglial response to increasing amyloid load saturates with aging: A longitudinal dual tracer in vivo μPET-study. *Journal of NeuroInflammation*, 15, 307. https://doi.org/10.1186/s12974-018-1347-6

Boeras, D. I., Granic, A., Padmanabhan, J., Crespo, N. C., Rojiani, A. M., & Potter, H. (2008). Alzheimer’s presenilin 1 causes chromosome missegregation and aneuploidy. *Neurobiology of Aging*, 29, 319–328. https://doi.org/10.1016/j.neurobiolaging.2006.10.027

Borysov, S. I., Granic, A., Padmanabhan, J., Walczak, C. E., & Potter, H. (2011). Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. *Cell Cycle*, 10, 1397–1410. https://doi.org/10.4161/cc.10.15.11478

Boveri, T. (2008). Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. *Journal of Cell Science*, 121(Supplement 1), 1–84. https://doi.org/10.1242/jcs.025742

Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathologica*, 82(4), 239–259. https://doi.org/10.1007/BF00308809

Brennan, C. M., Vaites, L. P., Wells, J. N., Santaguida, S., Paulo, J. A., Storchova, Z., et al. Amon, A. (2019). Protein aggregation mediates stoichiometry of protein complexes in aneuploid cells. *Genes & Development*, 33, 1031–1047. https://doi.org/10.1101/gad.327494.119

Brunden, K. R., Lee, V. M., Smith, A. B. 3rd, Trojanowski, J. Q., & Ballatore, C. (2017). Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. *Neurobiology of Diseases*, 105, 328–335. https://doi.org/10.1016/j.nbd.2016.12.021

Brunden, K. R., Yao, Y., Potuzak, J. S., Ferrer, N. I., Ballatore, C., James, M. J., et al. Lee, V-Y. (2011). The characterization of microtubule-stabilizing
Folk, W. P., Kumari, A., Iwasaki, T., Pyndiah, S., Johnson, J. C., Cassimere, E. K., ... Sakamura, D. (2019). Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. *Journal of Biological Chemistry*, 294, 5700–5719. https://doi.org/10.1074/jbc.RA118.005699

Folenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. *British Journal of Psychiatry*, 198, 351–356. https://doi.org/10.1192/bjp.bp.110.080044

Franke, J. M., & López-Sánchez, N. (2010). A novel hypothesis for Alzheimer disease based on neuronal tetraploidy induced by p75 (NTR). *Cell Cycle*, 9, 1934–1941.

Fu, Q., Huang, Y., Ge, C., Li, Z., Tian, H., Li, Q., ... Song, X. (2019). SHIP1 inhibits cell growth, migration, and invasion in non-small cell lung cancer through the PI3K/AKT pathway. *Oncology Reports*, 41, 2337–2350. https://doi.org/10.3822/or.2019.6990

Götz, J., David, D., Hoernndl, F., Ke, Y. D., Schonrock, N., Wiesner, A., ... Ittner, L. M. (2008). Functional genomics dissect pathomechanisms in tauopathies: Mitosis failure and unfolded protein response. *Neurodegenerative Diseases*, 5, 179–181. https://doi.org/10.1159/000113696

Granic, A., & Potter, H. (2013). Mitotic spindle defects and chromosome mis-segregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer’s disease, and atherosclerosis. *PLoS ONE*, 8, e60718. https://doi.org/10.1371/journal.pone.0060718

Haas, J. G., & Lathe, R. (2018). Microbes and Alzheimer’s disease: New findings call for a paradigm change. Trends in *Neurosciences*, 41, 570–573. https://doi.org/10.1016/j.tins.2018.07.001

Hampel, H., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., ... Alzheimer Precision Medicine Initiative (APMI) (2018). Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. *Journal of Alzheimer’s Disease*, 64, S47–S105. https://doi.org/10.3233/JAD-179932

Iourov, I. Y., Vorsanova, S. G., Liehr, T., & Yurov, Y. B. (2009). Aneuploidy in the normal, Alzheimer’s disease and ataxia-telangiectasia brain: Differential expression and pathological meaning. *Neurobiology of Diseases*, 34, 212–220. https://doi.org/10.1016/j.nbd.2009.01.003

Jankowsky, J. L., & Zheng, H. (2017). Practical considerations for choosing a mouse model of Alzheimer’s disease. *Molecular Neurodegeneration*, 12, 89. https://doi.org/10.1186/s13024-017-0231-7

Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., ... Posthuma, D. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. *Nature Genetics*, 51, 404–413. https://doi.org/10.1038/s41588-018-0311-9

Judge, M., Hornbeck, L., Potter, H., & Padmanabhan, J. (2011). Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centromeres. *Molecular Neurodegeneration*, 6, 80. https://doi.org/10.1186/1750-1326-6-80

Jun, G. R., Chung, J., Mez, J., Barber, R., Beecham, G. W., Bennett, D. A., ... Zhang, X. (2017). Transectomic genome-wide scan identifies novel Alzheimer’s disease loci. *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*, 13, 727–738. https://doi.org/10.1016/j.jalz.2016.12.012

Kaisari, S., Shomer, P., Ziv, T., Sitry-Shevah, D., Minioviits-Shemtov, S., Teichner, A., & Herskho, A. (2019). Role of Polo-like kinase 1 in the regulation of the action of p31comet in the disassembly of mitotic checkpoint complexes. *Proceedings of the National Academy of Sciences of the United States of America*, 116, 11725–11730. https://doi.org/10.1073/pnas.1902970116

Kim, J. H. (2018). Genetics of Alzheimer’s disease. *Dementia and Neuropsychiatric Disorders*, 17, 131–136. https://doi.org/10.12779/ dnd.2018.17.4.131

Kang, H.-S. (2019). TREM2 acts as a tumor suppressor in colorectal...
carcinoma through Wnt1/β-catenin and Erk signaling. Cancers (Basel), 11, E1315. https://doi.org/10.3390/cancers11091315

Kirov, L., Rajic, A. J., Cribs, D. H., & Padmanabhan, J. (2017). Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer’s disease. eNeuro, 4, pii: ENEURO.0149-16.2017. https://doi.org/10.1523/ENEURO.0149-16.2017

Klein, W. L., Stine, W. B. Jr, & Teplov, D. B. (2004). Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiology of Aging, 25, 569–580.

Kobayashi, Y., Tobinai, K., Takeshita, A., Naito, K., Asai, O., Dobashi, N., ... Ohno, R. (2009). Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: Final results of Japanese multicenter cooperative study. International Journal of Hematology, 89, 460–469. https://doi.org/10.1007/s12185-009-0298-1

Kondratick, C. M., & Vandré, D. D. (1996). Alzheimer’s disease neurofibrillary tangles contain mitosis-specific phosphoepitopes. Journal of Neurochemistry, 67, 2405–2416. https://doi.org/10.1002/j.1471-4159.1996.67062405.x

Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., ... Nedergaard, M. (2014). Impairment of paravascular clearance pathways in the aging brain. Annals of Neurology, 76, 845–861. https://doi.org/10.1002/ana.24271

Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., ... Pericak-Vance, M. A. (2019). Genetic meta-analysis of disease modifiers of amyloid-P3, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A collaborative analysis of 25 cohorts. Nature Genetics, 51, 414–430. https://doi.org/10.1038/s41588-019-0358-2

Kuroda, T., Toyama, Y., Watanabe, Y., Nakanishi, K., ... Takahashi, R. (2012). Ectopic overexpression of Klf4 reverses memory impairment induced by Amyloid-β1-42 oligomers in mice. Pharmacological Research, 106, 10–20. https://doi.org/10.1016/j.phrs.2016.02.007

Lee, L. W., Bain, J. M., Lowes, C., Gow, N. A., & Erwig, L. P. (2012). Candida albicans infection inhibits macrophage cell division and proliferation. Fungal Genetics and Biology, 49, 679–680. https://doi.org/10.1016/j.fgb.2012.05.007

Lee, H., Liu, C. C., Zheng, H., & Huang, T. Y. (2018). Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl Neurodegener, 7, 34. https://doi.org/10.1186/s40035-018-0139-3

Li, H., Radford, J. C., Ragusa, M. J., Shea, K. L., McKercher, S. R., Zaremba, J. D., ... Lipton, S. A. (2008). Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105, 9397–9402. https://doi.org/10.1073/pnas.0802876105

Lipinski, C. A., Tran, N. L., Menashi, E., Rohi, C., Kloss, J., Bay, R. C., ... Loftus, J. C. (2005). The tyrosine kinase Pyk2 promotes migration and invasion of glioma cells. Neoplasia, 7(5), 435–445. https://doi.org/10.1593/neo.04712

Liu, S. L., Wang, C., Jiang, T., Tan, L., Xing, A., & Yu, J. T. (2016). The role of Cdk5 in Alzheimer’s disease. Molecular Neurobiology, 53, 4328–4342. https://doi.org/10.1007/s12035-015-9369-x

Liu, S., Zhang, W., Liu, K., Ji, B., & Wang, G. (2015). Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep, 11, 59–62. https://doi.org/10.3892/mmr.2014.2652

Lomonte, P., & Everett, R. D. (1999). Herpes simplex virus type 1 immediate-early protein Vm110 inhibits progression of cells through mitosis and from G1 into S phase of the cell cycle. Journal of Virology, 73, 9456–9467. https://doi.org/10.1128/JVI.73.11.9456-9467.1999

Lopes, J. P., & Agostinho, P. (2011). Cdk5: Multitasking between physiological and pathological conditions. Progress in Neurobiology, 94, 49–63. https://doi.org/10.1016/j.pneurobio.2011.03.006

Lopes, J. P., Burton-Jones, M., Yamasaki, T. R., Agostinho, P., & LaFerla, F. M. (2009). Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. Journal of Alzheimer’s Disease, 16, 541–549. https://doi.org/10.3233/JAD-2009-0993

López-Sánchez, N., Fontán-Lozano, Á., Pallé, A., González-Álvarez, V., Rábano, A., Trejo, J. L., & Frade, J. M. (2017). Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology. Neurobiology of Aging, 56, 50–66. https://doi.org/10.1016/j.neurobiolaging.2017.04.008

López-Sánchez, N., Müller, U., & Frade, J. M. (2005). Lengthening of G2/mitosis in cortical precursors from mice lacking beta-amyloid precursor protein. Neuroscience, 130, 51–60.

Lott, I. T., & Head, E. (2019). Dementia in down syndrome: Unique insights for Alzheimer disease research. Nature Reviews Neurology, 15, 135–147. https://doi.org/10.1038/s41582-018-0132-6

Lovestone, S., Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., ... del Ser, T. (2015). A phase II trial of tideglibiz in Alzheimer’s disease. Journal of Alzheimer’s Disease, 45, 75–88. https://doi.org/10.3233/JAD-141959

Mairet-Coello, G., & Polleux, F. (2014). Involvement of ‘stress-response’ kinase pathways in Alzheimer’s disease progression. Current Opinion in Neurobiology, 27, 110–117. https://doi.org/10.1016/j.conb.2014.03.011

Makani, V., Zhang, B., Han, H., Yao, Y., Lassalas, P., Lou, K., ... Brunden, K. R. (2016). Evaluation of the brain-penetrant microtubule-stabilizing agent, dicystatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathol Commun, 4, 106. https://doi.org/10.1186/s40478-016-0378-4

Matos, A., & Johnston, I. N. (2019). Chemotherapy-induced cognitive impairments: A systematic review of the animal literature. Neuroscience and Biobehavioral Reviews, 102, 382–399. https://doi.org/10.1016/j.neubiorev.2019.05.001

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., ... Bateman, R. J. (2010). Decreased clearance of CNS...
beta-amyloid in Alzheimer’s disease, Science, 330, 1774. https://doi.org/10.1126/science.1197623
Meng, X.-Q., Cui, B., Cheng, D., Lu, H., Jiang, L.-G., Zheng, K.-G., ... Zhou, J. (2018). Activated proline-rich tyrosine kinase 2 regulates meiotic spindle assembly in the mouse oocyte. Journal of Cellular Biochemistry, 119, 736–747. https://doi.org/10.1002/jcb.26237
Miao, H., Wei, B. R., Peehl, D. M., Li, Q., Alexandrou, T., Schelling, J. R., ... Wang, B. (2001). Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nature Cell Biology, 3(5), 527–530. https://doi.org/10.1038/35074604
Miners, J. S., Morris, S., Love, S., & Kehoe, P. G. (2011). Accumulation of insoluble amyloid-β in down’s syndrome is associated with increased BACE-1 and neprilysin activities. Journal of Alzheimer’s Disease, 23, 101–108. https://doi.org/10.3233/JAD-2010-101395
Mingari, M. C., Vitale, C., Romagnani, C., Falco, M., & Moretta, L. (2001). p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunological Reviews, 181, 260–268. https://doi.org/10.1034/j.1600-065X.2001.1810122.x
Mohamed, W. A., Salama, R. M., & Schaan, M. F. (2019). A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomedicine & Pharmacotherapy, 111, 714–723. https://doi.org/10.1016/j.biopharma.2018.12.118
Monaco, E. A. 3rd, & Vallano, M. L. (2005). Role of protein kinases in neurodegenerative disease: Cyclin-dependent kinases in Alzheimer’s disease. Frontiers in Bioscience, 10, 143–159. https://doi.org/10.2741/1516
Monzo, P., Gauthier, N. C., Kesimal, F., Loubat, A., Field, C. M., Le Marchand-Brustel, Y., & Cormont, M. (2005). Clues to CD2-associated protein involvement in cytokinesis. Molecular Biology of the Cell, 16, 2891–2902. https://doi.org/10.1091/mbc.e04-09-0773
Morroni, F., Sita, G., Tarozzi, A., Rimondini, R., & Hrelia, P. (2016). Early effects of Aj1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways. Behavioral Brain Research, 314, 106–115. https://doi.org/10.1016/j.bbr.2016.08.002
Moussa-Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al-Tel, T. H. (2019). BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease. Medicinal Research Reviews, 40(1), 339–384. https://doi.org/10.1002/mrd.21622
Muresan, Z., & Muresan, V. (2007). The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. Molecular Biology of the Cell, 18, 3835–3844.
Murray, A., & Hunt, T. (1993). The cell cycle: An introduction. New York, NY: Oxford University Press.
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011). Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: A retrospective study. The Lancet Neurology, 10, 785–796. https://doi.org/10.1016/S1474-4422(11)70156-9
Mushqat, G., Greig, N. H., Anwar, F., Al-Abassi, F. A., Zamzami, M. A., Al-Tahhi, H. A., & Kamal, M. A. (2016). Neuroprotective mechanisms mediated by CDK5 inhibition. Current Pharmaceutical Design, 22, 527–534. https://doi.org/10.2174/13816128226615112425028
Nelson, T. J., Sun, M. K., Lim, C., Sen, A., Khan, T., Chirila, F. V., & Alkon, D. L. (2017). Bryostatin effects on cognitive function and PKCz in Alzheimer’s disease phase Ila and expanded access trials. Journal of Alzheimer’s Disease, 58, 521–535. https://doi.org/10.3233/JAD-170161
Neve, R. L., & McPhie, D. L. (2006). The cell cycle as a therapeutic target for Alzheimer’s disease. Pharmacology & Therapeutics, 111, 99–113. https://doi.org/10.1016/j.pharmthera.2005.09.005
Nordengen, K., Kirsebom, B. E., Henjum, K., Selnes, P., Gisladöttir, B., Wettgren, M., ... Fladby, T. (2019). Gliol activation and inflammation along the Alzheimer’s disease continuum.
Alzheimer’s disease. *Cell*, 153, 707–720. https://doi.org/10.1016/j.cell.2013.03.030

Zhang, Q., Guo, S., Zhang, X., Tang, S., Shao, W., Han, X., ... Du, Y. (2015). Inverse relationship between cancer and Alzheimer’s disease: A systemic review meta-analysis. *Neurological Sciences*, 36, 1987–1994. https://doi.org/10.1007/s10072-015-2282-2

Zhang, S., Liu, X., Zhang, Y., Cheng, Y., & Li, Y. (2013). RNAi screening identifies KAT8 as a key molecule important for cancer cell survival. *International Journal of Clinical and Experimental Pathology*, 6, 870–877.

Zhang, X., Hernandez, I., Rei, D., Mair, W., Laha, J. K., Cornwell, M. E., ... Kosik, K. S. (2013). Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. *The Journal of Biological Chemistry*, 288, 22042–22056. https://doi.org/10.1074/jbc.M112.436402

Zhang, Y., Zhang, Y., Xiao, Y., Zhong, C., & Xiao, F. (2019). Expression of Clusterin suppresses Cr(VI)-induced premature senescence through activation of PI3K/AKT pathway. *Ecotoxicology and Environmental Safety*, 183, 109465. https://doi.org/10.1016/j.ecoenv.2019.109465

Zheng, H., Jia, L., Liu, C.-C., Rong, Z., Zhong, L. I., Yang, L., ... Bu, G. (2017). TREM2 promotes microglial survival by activating Wnt/β-catenin pathway. *Journal of Neuroscience*, 37, 1772–1784. https://doi.org/10.1523/JNEUROSCI.2459-16.2017

Zhong, L. I., Zhang, Z.-L., Li, X., Liao, C., Mou, P., Wang, T., ... Chen, X.-F. (2017). TREM2/DAP12 complex regulates inflammatory responses in microglia via the JNK signaling pathway. *Frontiers in Aging Neuroscience*, 9, 204. https://doi.org/10.3389/fnagi.2017.00204

Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., ... Wang, Q.-F. (2014). PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. *Leukemia*, 28, 1436–1448. https://doi.org/10.1038/leu.2013.384

Zhu, X., Lee, H. G., Perry, G., & Smith, M. A. (2007). Alzheimer disease, the two-hit hypothesis: An update. *Biochimica et Biophysica Acta*, 1772, 494–502. https://doi.org/10.1016/j.bbadis.2006.10.014

Zhu, X., Raina, A. K., Perry, G., & Smith, M. A. (2004). Alzheimer’s disease: The two-hit hypothesis. *The Lancet Neurology*, 3, 219–226. https://doi.org/10.1016/S1474-4422(04)00707-0

Zhu, X., Rottkamp, C. A., Raina, A. K., Brewer, G. J., Ghanbari, H. A., Boux, H., & Smith, M. A. (2000). Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease. *Neurobiology of Aging*, 21, 807–813. https://doi.org/10.1016/S0197-4580(00)00217-7

Zhu, Z., & Wang, X. (2019). Roles of cohesin in chromosome architecture and gene expression. *Seminars in Cell & Developmental Biology*, 90, 187–193. https://doi.org/10.1016/j.semcdb.2018.08.004

Zivkovic, L., Spremo-Potparevic, B., Plecas-Solarovic, B., Djelic, N., Ocic, G., Smiljkovic, P., ... Bajic, V. (2010). Premature centromere division of metaphase chromosomes in peripheral blood lymphocytes of Alzheimer’s disease patients: Relation to gender and age. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 65, 1269–1274. https://doi.org/10.1093/gerona/glq148

How to cite this article: Rao CV, Asch AS, Carr DJJ, Yamada HY. “Amyloid-beta accumulation cycle” as a prevention and/or therapy target for Alzheimer’s disease. *Aging Cell*. 2020;19:e13109. https://doi.org/10.1111/acel.13109